Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals.
Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.
U.S. payers have generated a lot of ink protesting against high drug prices. After all, headlines about expensive meds--and patients who can't get them--are catnip for readers.
Shire is casting off on its own after AbbVie pulled the plug on its $55 billion proposed deal. But the Dublin-based company is losing more than just a merger, as one of its top dogs is jumping ship and joining a U.K. water firm.
To settle or not to settle? That's always the question in drugmaker lawsuits, but Purdue Pharma faces a more dramatic choice than most in a Kentucky lawsuit. As Bloomberg reports, the state accuses the OxyContin maker of Medicaid fraud, false advertising, and 10 other claims--but the addiction epidemic is the crux of the matter.
Valeant may have upped its Q3 revenue by 33% and beat analysts' bottom-line expectations--not to mention hiked its forecast for this year and next. But takeover target Allergan still isn't impressed. On the other hand, shareholders might be if Valeant hikes its hostile bid again, as its CEO now suggests.
Vertex' orphan drug Kalydeco boasts a comparatively small patient pool that the drugmaker is trying to swell, with an eye on adding cystic fibrosis patients with the R117H mutation. But first, it'll have to get the FDA's OK, and new briefing documents suggest the agency still has some doubts.
Prime Minister Narendra Modi got an ear full from both constituents and the U.S. drug industry about India's approach to drug patents during his first visit to the U.S. last month. Three weeks later, there is evidence the government will take a considered approach to the contested issue.
It's been a long road for Baxter's primary immunodeficiency replacement therapy in the U.S., but the Illinois company is finally preparing to roll out the med in its home country. And with its biopharma spinoff on the calendar for next year, a solid launch is something the drugmaker could use.
Breaking up is hard to do, and can be expensive. AbbVie is getting into record territory with the $1.635 billion breakup fee it will have to pay Shire for canceling their $55 billion deal.
It has been a tale of two cities when it comes to Eli Lilly's operations in Puerto Rico. Its plant in Carolina has been slotted for $240 million in investments in the last year, benefiting from its buildup in insulin products, and its plant in Guayama is getting axed, a victim of patent losses.
Pfizer's controversial smoking-cessation drug Chantix will continue to be stuck with a black-box warning label at least until late next year, assuming the U.S. Food and Drug Administration follows the recommendations of its experts.
Teva's been waiting a long time to get its Copaxone patent appeal before the Supreme Court. And now that the court has heard oral arguments, it seems to be divided on the issue.
There's nothing like same-day FDA approvals to trigger a market showdown--and that's the case for a pair of new idiopathic pulmonary fibrosis (IPF) treatments. After snagging nods from the agency Wednesday, Roche's Esbriet and Boehringer Ingelhem's Ofev will be going head-to-head.
Now that AbbVie has said it wants to dump Shire, we could soon have two companies back on the market--and both could prove popular as the dust settles. In fact, as Bloomberg reports, AbbVie could make a decent second choice to AstraZeneca if Pfizer so chooses.
Hospira, the country's largest producer of sterile drugs, is recalling two dozen lots of saline solution, along with 30 lots of other products, because the bags on one of its delivery systems can leak and products might get contaminated.
Another one bites the dust in the Big Pharma megamerger craze. Weeks after the U.S. Treasury Department laid out new tax rules to limit the stream of corporate inversions, AbbVie called it quits on its proposed $55 billion takeover of Dublin-based Shire.
Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.
Pharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned.
The U.K.'s cost-effectiveness watchdog has recently sounded a bit like a broken record when it comes to its cancer drug rejections. The latest to get a "no-go" from the gatekeeper? Celgene's Imnovid.